TY-2136b
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 282 patients (estimated)
- Sponsors
- TYK Medicines, Inc, TYK Medicines, Inc
- Tags
- Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1443
- NCT Identifier
- NCT05769075
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.